Table 3. Reactivity of discovery set and validation set sera from women who subsequently developed breast cancer (cases) and controls.
| MUC1 peptide/glycopeptide antigen | Samples | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|---|
|
(A) Discovery set | |||||
| MUC1 peptide unglycosylated (60mer) | Cases | 66 | 70 | 61 | 76 |
| Controls | 70 | 67 | 75 | 61 | |
| |
P-value |
0·732 |
0·798 |
0·230 |
0·200 |
| MUC1core3 glycopeptide (60mer) | Cases | 63 | 63 | 66 | 81 |
| Controls | 73 | 73 | 71 | 56 | |
| |
P-value |
0·391 |
0·391 |
0·670 |
0·0327 |
| MUC1STn glycopeptide (60mer) | Cases | 67 | 68 | 60 | 78 |
| Controls | 69 | 68 | 77 | 59 | |
| |
P-value |
0·864 |
1 |
0·146 |
0·105 |
| MUC1Tn glycopeptides (60mer) | Cases | 62 | 60 | 69 | 82 |
| Controls | 74 | 77 | 67 | 55 | |
| |
P-value |
0·303 |
0·146 |
0·864 |
0·0210 |
| MUC1T glycopeptides (60mer) | Cases | 69 | 60 | 70 | 74 |
| Controls | 67 | 77 | 66 | 63 | |
| |
P-value |
0·864 |
0·146 |
0·732 |
0·347 |
| MUC1T CHO recombinant (16 tandem repeats) | Cases | 64 | 68 | 68 | 73 |
| Controls | 72 | 69 | 68 | 64 | |
| |
P-value |
0·492 |
0·932 |
1 |
0·442 |
| MUC1Tn CHO recombinant (16 tandem repeats) | Cases | 58 | 70 | 70 | 75 |
| Controls | 78 | 67 | 66 | 62 | |
| |
P-value |
0·086 |
0·798 |
0·732 |
0·267 |
| MUC1ST CHO recombinant (16 tandem repeats) | Cases | 62 | 61 | 73 | 77 |
| Controls | 74 | 75 | 64 | 60 | |
| |
P-value |
0·303 |
0·230 |
0·442 |
0·146 |
| MUC2core3 glycopeptide | Cases | 61 | 71 | 71 | 70 |
| Controls | 74 | 67 | 65 | 65 | |
| |
P-value |
0·263 |
0·733 |
0·607 |
0·798 |
|
(B) Validation set | |||||
|
UKCTOCS cohort |
|
|
|
|
|
| MUC1 peptide unglycosylated | Cases | 109 | 108 | 106 | 103 |
| (60mer) | Controls | 104 | 105 | 107 | 110 |
| |
P-value |
0·732 |
0·837 |
0·945 |
0·631 |
| MUC1core3 glycopeptides (60mer) | Cases | 108 | 97 | 114 | 107 |
| Controls | 105 | 116 | 99 | 106 | |
| |
P-value |
0·837 |
0·193 |
0·304 |
0·945 |
| MUC1STn glycopeptides (60mer) | Cases | 103 | 108 | 110 | 105 |
| Controls | 110 | 105 | 103 | 108 | |
| |
P-value |
0·631 |
0·837 |
0·631 |
0·837 |
| MUC1Tn glycopeptides (60mer) | Cases | 115 | 93 | 105 | 113 |
| Controls | 98 | 120 | 108 | 100 | |
| |
P-value |
0·244 |
0·064 |
0·837 |
0·373 |
| MUC1T CHO recombinant | Cases | 105 | 113 | 96 | 112 |
| (16 tandem repeats) | Controls | 108 | 100 | 117 | 101 |
| |
P-value |
0·837 |
0·373 |
0·150 |
0·451 |
| MUC1Tn CHO recombinant | Cases | 103 | 103 | 107 | 113 |
| (16 tandem repeats) | Controls | 110 | 110 | 106 | 100 |
| |
P-value |
0·631 |
0·631 |
0·945 |
0·373 |
| MUC1ST CHO recombinant | Cases | 115 | 106 | 98 | 107 |
| (16 tandem repeats) | Controls | 98 | 107 | 115 | 106 |
| P-value | 0·244 | 0·945 | 0·244 | 0·945 | |
|
Guernsey cohort | |||||
| MUC1 peptide unglycosylated | Cases | 74 | 66 | 78 | 85 |
| (60mer) | Control 1 | 77 | 69 | 86 | 71 |
| Control 2 | 76 | 92 | 64 | 71 | |
| |
P-value |
0·806 |
0·796 |
0·532 |
0·262 |
| MUC1core3 glycopeptides (60mer) | Cases | 77 | 68 | 84 | 74 |
| Control 1 | 78 | 79 | 76 | 70 | |
| Control 2 | 72 | 80 | 68 | 83 | |
| |
P-value |
0·936 |
0·364 |
0·527 |
0·739 |
| MUC1STn glycopeptides (60mer) | Cases | 79 | 78 | 72 | 74 |
| Control 1 | 72 | 78 | 77 | 76 | |
| Control 2 | 76 | 71 | 79 | 77 | |
| |
P-value |
0·569 |
1 |
0·682 |
0·870 |
| MUC1Tn glycopeptides (60mer) | Cases | 73 | 72 | 76 | 82 |
| Control 1 | 81 | 79 | 79 | 64 | |
| Control 2 | 73 | 76 | 73 | 81 | |
| |
P-value |
0·519 |
0·569 |
0·809 |
0·136 |
| MUC1T CHO recombinant (16 tandem repeats) | Cases | 83 | 74 | 71 | 75 |
| Control 1 | 70 | 80 | 74 | 79 | |
| Control 2 | 74 | 73 | 83 | 73 | |
| |
P-value |
0·293 |
0·629 |
0·803 |
0·240 |
| MUC1Tn CHO recombinant (16 tandem repeats) | Cases | 84 | 75 | 66 | 78 |
| Control 1 | 75 | 82 | 82 | 64 | |
| Control 2 | 68 | 70 | 80 | 85 | |
| |
P-value |
0·475 |
0·576 |
0·188 |
0·240 |
| MUC1ST CHO recombinant (16 tandem repeats) | Cases | 78 | 81 | 74 | 70 |
| Control 1 | 75 | 70 | 71 | 87 | |
| Control 2 | 74 | 76 | 83 | 70 | |
| P-value | 0·808 | 0·370 | 0·803 | 0·175 | |
Abbreviation: UKCTOCS=UK Collaborative Trial of Ovarian Cancer Screening.
Cases and controls were divided into quartiles dependent on the reactivity of their sera with the indicated antigens.